Press Release for Commencement of Commercial Production
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Corona Remedies has started commercial production at its new EU-GMP approved Women's Hormone manufacturing facility at Bhayla, Ahmedabad. The 1.0 lakh sq. ft. facility has an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels, and is expected to increase the company's in-house hormone manufacturing capacity by nearly 20%. It supports multiple dosage forms including tablets, soft gel capsules, ointments, and gels, enabling the company to cater to both domestic and international markets. The facility features advanced technologies such as closed-loop manufacturing systems, 21 CFR-compliant equipment, and real-time online process monitoring. The move aligns with growing global demand for women's healthcare, including fertility care and hormone replacement therapies.
This capacity expansion strengthens Corona Remedies' positioning in the fast-growing women's healthcare segment and, with EU-GMP certification, opens doors to regulated export markets. Shareholders can expect potential revenue uplift from higher volumes and improved margins, though near-term financial impact will depend on capacity utilization.